RT Journal Article
SR Electronic
T1 Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.22.23284881
DO 10.1101/2023.01.22.23284881
A1 Nugent, Clare
A1 Abul, Yasin
A1 White, Elizabeth
A1 Shehadeh, Fadi
A1 Kaczynski, Matthew
A1 Felix, Lewis Oscar
A1 Ganesan, Narchonai
A1 Oyebanji, Oladayo A.
A1 Vishnepolskiy, Igor
A1 Didion, Elise M.
A1 Paxitzis, Alexandra
A1 Sheehan, Maegan L.
A1 Mylonakis, Eleftherios
A1 Wilson, Brigid M.
A1 Balazs, Alejandro B.
A1 Chan, Philip A.
A1 King, Christopher L.
A1 Pfeifer, Walther M.
A1 Dickerson, Evan
A1 Canaday, David H.
A1 Gravenstein, Stefan
YR 2023
UL http://medrxiv.org/content/early/2023/01/25/2023.01.22.23284881.abstract
AB We examined whether the second monovalent SARS-CoV-2 mRNA booster increased antibody levels and their neutralizing activity to Omicron variants in nursing home residents (NH) residents and healthcare workers (HCW). We sampled 367 NH residents and 60 HCW after primary mRNA vaccination, first and second boosters, for antibody response and pseudovirus neutralization assay against SARS-CoV-2 wild-type (WT) (Wuhan-Hu-1) strain and Omicron BA1 variant. Antibody levels and neutralizing activity progressively increased with each booster but subsequently waned over weeks. NH residents, both those without and with prior infection, had a robust geometric mean fold rise (GMFR) of 10.2 (95% CI 5.1, 20.3) and 6.5 (95% CI 4.5, 9.3) respectively in Omicron-BA.1 subvariant specific neutralizing antibody levels following the second booster vaccination (p<0.001). These results support the ongoing efforts to ensure that both NH residents and HCW are up to date on recommended SARS-CoV-2 vaccine booster doses.Competing Interest StatementThis work was supported by NIH AI129709-03S1, CDC 200-2016-91773, U01 CA260539- 01, and VA BX005507-0 Stefan Gravenstein (S. G.) and David H. Canaday (D. H. C.) are recipients of investigator initiated grants to their universities from Pfizer to study pneumococcal vaccines and Sanofi Pasteur and Seqirus to study influenza vaccines, and S.G. from Genentech on influenza antivirals. S. G. also does consulting for Seqirus, Sanofi, Merck, Vaxart, Novavax, Moderna and Janssen, has served on the speaker's bureaus for Seqirus and Sanofi and reports personal fees from Pfizer and data and safety monitoring board (DSMB) fees from Longevoron and SciClone. Funding StatementThis work was supported by NIH AI129709-03S1, CDC 200-2016-91773, U01 CA260539- 01, and VA BX005507-01Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Western Institutional Review Board-Copernicus Group. All participating individuals or their legally authorized representatives provided informed consent to be recruited into the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors